FILE 'HOME' ENTERED AT 16:35:56 ON 10 JUL 2003

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:36:06 ON 10 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUL 2003 HIGHEST RN 545225-95-4
DICTIONARY FILE UPDATES: 9 JUL 2003 HIGHEST RN 545225-95-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s 66611-38-9
L1 1 66611-38-9
(66611-38-9/RN)

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN **66611-38-9** REGISTRY
CN 3-Pyridinecarboximidamide, N-[2-hydroxy-3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN NP 51
FS 3D CONCORD
DR 79104-68-0
MF C14 H22 N4 O2
CI COM
LC STN Files: BEILSTEIN*, CA, CAPLUS, DRUGUPDATES, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1957 TO DATE)
15 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> s BGP-15
36 BGP
399266 15

L2 1 BGP-15
(BGP(W)15)

=> d l2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 66611-37-8 REGISTRY
CN 3-Pyridinecarboximidamide, N-[2-hydroxy-3-(1-piperidinyl)propoxy]-, dihydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **BGP 15**
MF C14 H22 N4 O2 . 2 Cl H
LC STN Files: BIOSIS, CA, CAPLUS, CIN, DRUGUPDATES, PROMT, SYNTHLINE, TOXCENTER, USPATFULL
CRN (66611-38-9)



●2 HCl

11 REFERENCES IN FILE CA (1957 TO DATE)
11 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> s floxuridine
L3 1 FLOXURIDINE

=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 50-91-9 REGISTRY
CN Uridine, 2'-deoxy-5-fluoro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-(2-Deoxy-.beta.-D-ribofuranosyl)-5-fluorouracil
CN 2'-Deoxy-5-fluorouridine
CN 5-Fluoro-2'-deoxy-.beta.-uridine
CN 5-Fluoro-2'-deoxyuridine
CN 5-Fluorodeoxyuridine
CN 5-Fluorouracil 2'-deoxyriboside
CN 5-Fluorouracil deoxyriboside
CN FdUrd
CN Floxuridin
CN **Floxuridine**
CN FUDR
CN NSC 26740
CN NSC 27640
FS STEREOSEARCH
DR 888-03-9, 3460-74-0
MF C9 H11 F N2 O5
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHARMASEARCH, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2091 REFERENCES IN FILE CA (1957 TO DATE)
63 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2095 REFERENCES IN FILE CAPLUS (1957 TO DATE)
34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s idouridine
L4 0 IDOURIDINE

=> s idoxuridine
L5 2 IDOXURIDINE

=> d l5

L5 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2003 ACS
RN 112541-23-8 REGISTRY
CN Uridine, 2'-deoxy-5-iodo-, mixt. with (2,5-dioxo-4-imidazolidinyl)urea, neomycin sulfate and sulfur (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Neomycin, sulfate, mixt. contg. (9CI)
CN Sulfur, mixt. contg. (9CI)
CN Urea, (2,5-dioxo-4-imidazolidinyl)-, mixt. contg. (9CI)
OTHER NAMES:
CN **Allantoin-idoxuridine-neomycin sulfate-sulfur mixt.**
FS STEREOSEARCH
MF C9 H11 I N2 O5 . C4 H6 N4 O3 . H2 O4 S . S . x Unspecified
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 7704-34-9
CMF S

S

CM 2

CRN 97-59-6
CMF C4 H6 N4 O3



CM 3

CRN 54-42-2
CMF C9 H11 I N2 O5

Absolute stereochemistry. Rotation (+).



CM 4

CRN 1405-10-3
CMF H2 O4 S . x Unspecified

CM 5

CRN 7664-93-9
CMF H2 O4 S



CM 6

CRN 1404-04-2
CMF Unspecified
CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> s doxifluridine
L6 1 DOXIFLURIDINE

=> d l6

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 3094-09-5 REGISTRY
CN Uridine, 5'-deoxy-5-fluoro- (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:
CN 5'-Deoxy-5-fluorouridine
CN 5'-DFUR
CN 5'-dFUrd
CN 5-Fluoro-5'-deoxyuridine
CN 5-Fluorodesoxyuridine
CN **Doxifluridine**
CN Flutron
CN Furtulon
CN Ro 21-9738
FS STEREOSEARCH
MF C9 H11 F N2 O5
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

470 REFERENCES IN FILE CA (1957 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
473 REFERENCES IN FILE CAPLUS (1957 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s cytarabine
L7 17 CYTARABINE

=> d 17

L7 ANSWER 1 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN 65093-40-5 REGISTRY
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[hydroxy(octadecyloxy)phosphinyl]-.beta.-D-arabinofuranosyl]-, monosodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Cytarabine ocfosfate**
CN Fosteabine sodium
FS STEREOSEARCH
MF C27 H50 N3 O8 P . Na
LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, CA, CAPLUS, DRUGPAT, DRUGUPDATES, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
CRN (73532-83-9)

Absolute stereochemistry.



● Na

20 REFERENCES IN FILE CA (1957 TO DATE)
20 REFERENCES IN FILE CAPLUS (1957 TO DATE)

```
=> s gemcitabine
L8             4 GEMCITABINE

=> d 18

L8   ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2003 ACS
RN   122111-03-9  REGISTRY
CN   Cytidine, 2'-deoxy-2',2'-difluoro-, monohydrochloride (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   Gemcitabine hydrochloride
CN   Gemzar
CN   LY 188011 hydrochloride
FS   STEREOSEARCH
MF   C9 H11 F2 N3 O4 . Cl H
SR   CA
LC   STN Files:   ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT,
       CAPLUS, CHEMCATS, CIN, CSCHEM, DIOGENES, DRUGPAT, DRUGUPDATES, EMBASE,
       IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN,
       USPAT2, USPATFULL
         (*File contains numerically searchable property data)
CRN  (95058-81-4)

Absolute stereochemistry.
```



● HCl

61 REFERENCES IN FILE CA (1957 TO DATE)
61 REFERENCES IN FILE CAPLUS (1957 TO DATE)

```
=> s ancitabine
```

L9 2 ANCITABINE

=> d l9

L9 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2003 ACS
RN 31698-14-3 REGISTRY
CN 6H-Furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol, 2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-, (2R,3R,3aS,9aR)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 6H-Furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol, 2,3,3a,9a-tetrahydro-3-hydroxy-6-imino- (6CI)
CN 6H-Furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol, 2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-, stereoisomer (8CI)
CN 6H-Furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol, 2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-, [2R-(2.alpha.,3.beta.,3a.beta.,9a.beta.)]-
OTHER NAMES:
CN 2,2'-Anhydro(1-.beta.-D-arabinofuranosyl)cytosine
CN 2,2'-Anhydroarabinosylcytosine
CN 2,2'-Anhydrocytidine
CN 2,2'-Cyclocytidine
CN 2,2'-O-Cyclocytidine
CN **Ancitabine**
CN Ancytabine
CN Cyclocytidine
CN O2,2'-Cyclocytidine
CN O2:2'-Anhydro-1-.beta.-D-arabinosylcytosine
FS STEREOSEARCH
DR 51743-54-5, 36258-39-6, 34939-46-3, 46488-37-3
MF C9 H11 N3 O4
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, RTECS*, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

205 REFERENCES IN FILE CA (1957 TO DATE)
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
206 REFERENCES IN FILE CAPLUS (1957 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s carmofur
L10 1 CARMOFUR

=> d l10

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 61422-45-5 REGISTRY
CN 1(2H)-Pyrimidinecarboxamide, 5-fluoro-N-hexyl-3,4-dihydro-2,4-dioxo- (9CI)

(CA INDEX NAME)
OTHER NAMES:
CN 1-(Hexylcarbamoyl)-5-fluorouracil
CN 1-(Hexylcarbamyl)-5-fluorouracil
CN 1-(n-Hexylcarbamoyl)-5-fluorouracil
CN **Carmofur**
CN HCFU
CN Mifurol
CN Yamaful
FS 3D CONCORD
MF C11 H16 F N3 O3
CI COM
LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, DDFU, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

215 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
215 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> s tegafur
L11 2 TEGAFUR

=> d l11

L11 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2003 ACS
RN 74578-38-4 REGISTRY
CN 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, mixt. with 2,4(1H,3H)-pyrimidinedione (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4(1H,3H)-Pyrimidinedione, mixt. contg. (9CI)
OTHER NAMES:
CN **Tegafur-uracil mixt.**
CN UFT
CN Uracil-Futraful mixt.
CN Youfuding
MF C8 H9 F N2 O3 . C4 H4 N2 O2
CI MXS
LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CIN, DRUGPAT, DRUGUPDATES, EMBASE, MEDLINE, PHAR, PROMT, RTECS*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 17902-23-7
CMF C8 H9 F N2 O3



CM 2

CRN 66-22-8
CMF C4 H4 N2 O2



283 REFERENCES IN FILE CA (1957 TO DATE)
288 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> s fluorouracil
L12 209 FLUOROURACIL

=> d l12

L12 ANSWER 1 OF 209 REGISTRY COPYRIGHT 2003 ACS
RN 502510-28-3 REGISTRY
CN Octanoic acid, (5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl)methyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **3-Octanoyloxymethyl-5-fluorouracil**
FS 3D CONCORD
MF C13 H19 F N2 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> file medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	73.12	73.33

FILE 'ADISCTI' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 16:42:10 ON 10 JUL 2003

FILE 'CAPLUS' ENTERED AT 16:42:10 ON 10 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 DERWENT INFORMATION LTD

FILE 'DRUGB' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBAL' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IPA' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 16:42:10 ON 10 JUL 2003

FILE 'NAPRALERT' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'NUTRACEUT' ENTERED AT 16:42:10 ON 10 JUL 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PASCAL' ENTERED AT 16:42:10 ON 10 JUL 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHARMAML' ENTERED AT 16:42:10 ON 10 JUL 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'SCISEARCH' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'TOXCENTER' ENTERED AT 16:42:10 ON 10 JUL 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 16:42:10 ON 10 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:42:10 ON 10 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1 or l2
  21 FILES SEARCHED...
L13   70 L1 OR L2

=> s hydroximic
L14   316 HYDROXIMIC

=> s l13 or l14
L15   370 L13 OR L14

=> s l3 and l15
  28 FILES SEARCHED...
L16   0 L3 AND L15

=> s l5 and l15
  23 FILES SEARCHED...
L17   0 L5 AND L15

```
=> s l6 and l15
  31 FILES SEARCHED...
L18             0 L6 AND L15

=> s l7 and l15
  21 FILES SEARCHED...
L19             0 L7 AND L15

=> s l8 and l15
  27 FILES SEARCHED...
L20             0 L8 AND L15

=> s l9 and l15
  24 FILES SEARCHED...
L21             0 L9 AND L15

=> s l10 and l15
  29 FILES SEARCHED...
L22             0 L10 AND L15

=> s l11 and l15
  25 FILES SEARCHED...
L23             0 L11 AND L15
```

```
=> s l13 and l3
  29 FILES SEARCHED...
L24             0 L13 AND L3

=> s l12 and l15
  10 FILES SEARCHED...
  31 FILES SEARCHED...
L25             6 L12 AND L15

=> d l25 1-6 bib abs kwic

L25  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2003 ACS
AN   1999:27740  CAPLUS
DN   130:90498
TI   Pharmaceutical composition having enhanced antitumor activity and/or
     reduced side effects, containing an antitumor agent and an hydroxamic acid
     derivative
IN   Sumegi, Balazs
PA   N-Gene Research Laboratories Inc., USA
SO   PCT Int. Appl., 45 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND  DATE          APPLICATION NO.  DATE
     ----------------    ----  --------      ---------------  --------
PI   WO 9858676          A1    19981230      WO 1998-IB961    19980622
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, GW, ID, IL, IS, JP, KE, KG, KP,
             KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,
             NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
             UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, ML, MR, NE, SN, TD, TG
     AU 9877837          A1    19990104      AU 1998-77837    19980622
     AU 735922           B2    20010719
     EP 993304           A1    20000419      EP 1998-925873   19980622
     EP 993304           B1    20030402
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     BR 9810312          A     20000919      BR 1998-10312    19980622
```

	JP 2002508762	T2	20020319	JP 1999-504049	19980622
	NZ 502039	A	20020328	NZ 1998-502039	19980622
	AT 235918	E	20030415	AT 1998-925873	19980622
	MX 9911656	A	20000930	MX 1999-11656	19991214
	NO 9906349	A	20000223	NO 1999-6349	19991220
	US 6440998	B1	20020827	US 2000-446064	20000217
	US 2002147213	A1	20021010	US 2002-84183	20020228
	US 2003050345	A1	20030313	US 2002-84095	20020228
	US 2003069270	A1	20030410	US 2002-106227	20020327
PRAI	HU 1997-1081	A	19970623		
	WO 1998-IB961	W	19980622		
	US 2000-446064	A3	20000217		

OS MARPAT 130:90498

AB Pharmaceutical compns. are provided which have an enhanced antitumor activity or reduced side effect(s), comprising a known active substance having antitumor effect, or a pharmaceutically acceptable salt thereof, and a **hydroximic** acid deriv. (Markush included) or a therapeutically useful acid addn. salt thereof. The **hydroximic** acid deriv. is e.g. O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Pharmaceutical compns. are provided which have an enhanced antitumor activity or reduced side effect(s), comprising a known active substance having antitumor effect, or a pharmaceutically acceptable salt thereof, and a **hydroximic** acid deriv. (Markush included) or a therapeutically useful acid addn. salt thereof. The **hydroximic** acid deriv. is e.g. O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime.

ST **hydroximic** acid deriv antitumor agent combination pharmaceutical; piperidinohydroxypropylnicotinic amidoxime antitumor agent combination pharmaceutical

IT Cytoprotective agents
(cardioprotective; **hydroximic** acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

IT Antitumor agents
Cytoprotective agents
Drug delivery systems
Drug interactions
Toxicity
(**hydroximic** acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

IT **Hydroximic** acids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hydroximic** acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

IT Antitumor agents
(leukemia; **hydroximic** acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

IT Antitumor agents
(sarcoma; **hydroximic** acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

IT **51-21-8**, Fluorouracil 15663-27-1, Cisplatin
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hydroximic** acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

IT **66611-37-8 66611-38-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**hydroximic** acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

L25 ANSWER 2 OF 6 TOXCENTER COPYRIGHT 2003 ACS
AN 1999:106651 TOXCENTER
CP Copyright 2003 ACS
DN CA13008090498Y
TI Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
AU Sumegi, Balazs
CS ASSIGNEE: N-Gene Research Laboratories Inc.
PI WO 9858676 A1 30 Dec 1998
SO (1998) PCT Int. Appl., 45 pp.
CODEN: PIXXD2.
CY UNITED STATES
DT Patent
FS CAPLUS
OS CAPLUS 1999:27740
LA English
ED Entered STN: 20011116
Last Updated on STN: 20020509
AB Pharmaceutical compns. are provided which have an enhanced antitumor activity or reduced side effect(s), comprising a known active substance having antitumor effect, or a pharmaceutically acceptable salt thereof, and a **hydroximic** acid deriv. (Markush included) or a therapeutically useful acid addn. salt thereof. The **hydroximic** acid deriv. is e.g. O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime.
AB. . . or reduced side effect(s), comprising a known active substance having antitumor effect, or a pharmaceutically acceptable salt thereof, and a **hydroximic** acid deriv. (Markush included) or a therapeutically useful acid addn. salt thereof. The **hydroximic** acid deriv. is e.g. O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime.
ST Miscellaneous Descriptors
hydroximic acid deriv antitumor agent combination pharmaceutical; piperidinohydroxypropylnicotinic amidoxime antitumor agent combination pharmaceutical
RN **51-21-8** (Fluorouracil)
15663-27-1 (Cisplatin)
RN **66611-37-8; 66611-38-9**

L25 ANSWER 3 OF 6 USPATFULL
AN 2003:100159 USPATFULL
TI Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an **hydroxImic** acid derivative
IN Sumegi, Balazs, Pecs, HUNGARY
PA N-Gene Research Laboratories, Inc. (non-U.S. corporation)
PI US 2003069270 A1 20030410
AI US 2002-106227 A1 20020327 (10)
RLI Division of Ser. No. US 2000-446064, filed on 17 Feb 2000, GRANTED, Pat. No. US 6440998 A 371 of International Ser. No. WO 1998-IB961, filed on 22 Jun 1998, UNKNOWN
PRAI HU 1997-P1081 19970623
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 804
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention refers to pharmaceutical compositions which have an enhanced antitumor activity or reduced side effect(s) comprising a known active substance having antitumor effect or a pharmaceutically

acceptable salt thereof and a **hydroximic** acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an **hydroxImic** acid derivative

AB . . . or reduced side effect(s) comprising a known active substance having antitumor effect or a pharmaceutically acceptable salt thereof and a **hydroximic** acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.

SUMM [0027] The U.S. Pat. No. 4,308,399 discloses compounds belonging to the scope of **hydroximic** acid derivatives of formula (I), which are useful for treatment of the diabetic angiopathy.

SUMM [0028] The EP-PS No. 417,210 describes **hydroximic** acid halides, which also fall into the scope of compounds of formula (I), possess a selective B-blocking effect and are. . .

SUMM [0029] HU-PS published under No. T/66350 discloses a number of other **hydroximic** acid derivatives being within the scope of compound of formula (I). These known substances are useful in the therapy of. . .

SUMM [0030] It is known from the PCT Patent Application published under No. WO 97/13504 that **hydroximic** acid derivatives of formula (I) are useful for the prevention and treatment of disorders of mitochondrial origin.

SUMM . . . agent or, if desired and possible, a therapeutically useful acid addition salt thereof or therepautically suitable salt thereof and a **hydroximic** acid derivative of formula (I), wherein E, R.sup.1, R.sup.2, R.sup.3, A, B, X and Y are as defined above, or. . .

SUMM [0043] With the compounds of formula (I), a preferable subgroup consists of **hydroximic** acid derivatives of formula (II), ##STR4##

SUMM [0049] A third preferred subgroup of **hydroximic** acid derivatives of formula (I) includes cyclic compounds of formula (IV), ##STR6##

SUMM [0051] A further preferred subgroup of **hydroximic** acid derivatives of formula (I) comprises compounds of formula (V), ##STR7##

SUMM . . . cisplatin as cytostatic (antitumor) active agent and 0-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime or a therapeutically useful acid addition salt thereof as a **hydroximic** acid derivative of formula (I).

DETD [0091] The attenuating effect of **hydroximic** acid derivative of the formula I on the side effects of cytostatics was investigated by testing the **hydroximic** acid derivative compound "L". The experiments and results are being discussed below.

DETD [0115] The antitumor effect of cytostatics in combination with **hydroximic** acid derivative of the formula I was investigated by testing the **hydroximic** acid derivative compound "L". The experiments and results are being discussed below.

DETD . . . which the patient is treated with a known antitumor compound or its pharmaceutically acceptable acid addition salt supplemented by a **hydroximic** acid derivative of the formula I or a pharmaceutically acceptable acid addition salt thereof in (1-50):(1-50)% by mass.

CLM What is claimed is:

. . . of a known active substance having antitumor effect, namely oxaliplatin i.e. (SP-4-2-(1R-trans))-(1,2-cyclohexanediamine-N,N') (ethanedioato(2-)-O,O') platinum and an effective amount of a **hydroximic** acid derivative of the formula (I) ##STR8## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-5 alkyl group, R.sup.2 stands. . .

2. The composition of claim 1, comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime or a physiologically acceptable acid addition salt thereof as the **hydroximic** acid derivative of the formula 1.

. . . an effective amount of a known active substance having antitumor

effect, namely oxaliplatin, and an effective non-toxic amount of a **hydroximic** acid derivative of the formula I, wherein R.sup.1, R.sup.2, R.sup.3, A, X, B, R and Y are as defined in. . . addition salt thereof to the patient, wherein said tumor is sensitive to said active substance; and the administration of the **hydroximic** acid derivative or a physiologically acceptable acid addition salt thereof reduces the neurotoxic and/or myelotoxic side effects experienced by the. . .

. . . 4. The method of claim 3, comprising administering O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a physiologically acceptable acid addition salt thereof as the **hydroximic** acid derivative of the formula I.

IT **51-21-8**, Fluorouracil 15663-27-1, Cisplatin
(hydroximic acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)
IT **66611-37-8 66611-38-9**
(hydroximic acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

L25 ANSWER 4 OF 6 USPATFULL
AN 2003:72058 USPATFULL
TI Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an **hydroximic** acid derivative
IN Sumegi, Balazs, Pecs, HUNGARY
PA N-Gene Research Laboratories, Inc. (non-U.S. corporation)
PI US 2003050345 A1 20030313
AI US 2002-84095 A1 20020228 (10)
RLI Division of Ser. No. US 2000-446064, filed on 17 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-IB961, filed on 22 Jun 1998, UNKNOWN
PRAI HU 1997-P1081 19970623
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 815
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention refers to pharmaceutical compositions which have an enhanced antitumor activity or reduced side effect(s) comprising a known active substance having antitumor effect or a pharmaceutically acceptable salt thereof and a **hydroximic** acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an **hydroximic** acid derivative
AB . . . or reduced side effect(s) comprising a known active substance having antitumor effect or a pharmaceutically acceptable salt thereof and a **hydroximic** acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.
SUMM [0005] **Hydroximic** acid derivatives of formula (I), ##STR1##
SUMM [0027] The U.S. Pat. No. 4,308,399 discloses compounds belonging to the scope of **hydroximic** acid derivatives of formula (I), which are useful for treatment of the diabetic angiopathy.
SUMM [0028] The EP-PS No. 417,210 describes **hydroximic** acid halides, which also fall into the scope of compounds of formula (I), possess a selective .beta.-blocking effect and are. . .
SUMM [0029] HU-PS published under No. T/66350 discloses a number of other **hydroximic** acid derivatives being within the scope of compound of formula (I). These known substances are useful in the therapy of. . .
SUMM [0030] It is known from the PCT Patent Application published under No. WO 97/13504 that **hydroximic** acid derivatives of formula (I)

are useful for the prevention and treatment of disorders of mitochondrial origin.

DETD . . . agent or, if desired and possible, a therapeutically useful acid addition salt thereof or therepautically suitable salt thereof and a **hydroximic** acid derivative of formula (I), wherein R, R.sup.1, R.sub.2, R.sup.3, A, B, X and Y are as defined above, or. . .

DETD [0044] With the compounds of formula (I), a preferable subgroup consists of **hydroximic** acid derivatives of formula (II), ##STR4##

DETD [0050] A third preferred subgroup of **hydroximic** acid derivatives of formula (I) includes cyclic compounds of formula (IV), ##STR6##

DETD [0052] A further preferred subgroup of **hydroximic** acid derivatives of formula (I) comprises compounds of formula (V), ##STR7##

DETD . . . cisplatin as cytostatic (antitumor) active agent and O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime or a therapeutically useful acid addition salt thereof as a **hydroximic** acid derivative of formula (I).

DETD [0200] The attenuating effect of **hydroximic** acid derivative of the formula I on the side effects of cytostatics was investigated by testing the **hydroximic** acid derivative compound "L". The experiments and results are being discussed below.

DETD [0224] The antitumor effect of cytostatics in combination with **hydroximic** acid derivative of the formula I was investigated by testing the **hydroximic** acid derivative compound "L". The experiments and results are being discussed below.

DETD . . . which the patient is treated with a known antitumor compound or its pharmaceutically acceptable acid addition salt supplemented by a **hydroximic** acid derivative of the formula I or a pharmaceutically acceptable acid addition salt thereof in (1-50):(1-50)% by mass.

CLM What is claimed is:

. . . chemically possible, a pharmaceutically suitable acid addition salt or a pharmaceutically suitable salt thereof and an effective amount of a **hydroximic** acid derivative of the formula I ##STR8## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-5 alkyl group, R.sup.2 stands. . .

. . . pharmaceutical composition as claimed in claim 1, comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime or a physiologically acceptable acid addition salt thereof as the **hydroximic** acid derivative of the formula I.

. . . comprising administering an effective amount of a known active substance having antitumor effect and an effective non-toxic amount of a **hydroximic** acid derivative of the formula I, wherein R.sup.1, R.sup.2, R.sup.3, A, X, B, R and Y are as defined in. . . cisplatin, carboplatin, paclitaxel, and docetaxel, and wherein said tumor is sensitive to said active substance; and the administration of the **hydroximic** acid derivative or a physiologically acceptable acid addition salt thereof reduces the side effects experienced by the patient requiring treatment. . .

. . . method as claimed in claim 6, comprising administering O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a physiologically acceptable acid addition salt thereof as the **hydroximic** acid derivative of the formula I.

IT **51-21-8**, Fluorouracil 15663-27-1, Cisplatin
(hydroximic acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

IT **66611-37-8 66611-38-9**
(hydroximic acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

L25 ANSWER 5 OF 6 USPATFULL

AN 2002:266334 USPATFULL

TI Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an

hydroximic acid derivative
IN Sumegi, Balazs, Pecs, HUNGARY
PA N-Gene Research Laboratories, Inc. (non-U.S. corporation)
PI US 2002147213 A1 20021010
AI US 2002-84183 A1 20020228 (10)
RLI Division of Ser. No. US 2000-446064, filed on 17 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-IB961, filed on 22 Jun 1998, UNKNOWN
PRAI HU 1997-P1081 19970623
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ##STR1##

The invention refers to pharmaceutical compositions which have an enhanced antitumor activity or reduced side effect(s) comprising a known active substance having antitumor effect or a pharmaceutically acceptable salt thereof and a **hydroximic** acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an **hydroximic** acid derivative
AB . . . or reduced side effect(s) comprising a known active substance having antitumor effect or a pharmaceutically acceptable salt thereof and a **hydroximic** acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.
SUMM [0005] **Hydroximic** acid derivatives of formula (I), ##STR2##
SUMM [0026] The U.S. Pat. No. 4,308,399 discloses compounds belonging to the scope of **hydroximic** acid derivatives of formula (I), which are useful for treatment of the diabetic angiopathy.
SUMM [0027] The EP-PS No. 417,210 describes **hydroximic** acid halides, which also fall into the scope of compounds of formula (I), possess a selective .beta.-blocking effect and are. . .
SUMM [0028] HU-PS published under No. T/66350 discloses a number of other **hydroximic** acid derivatives being within the scope of compound of formula (I). These known substances are useful in the therapy of. . .
SUMM [0029] It is known from the PCT Patent Application published under No. WO 97/13504 that **hydroximic** acid derivatives of formula (I) are useful for the prevention and treatment of disorders of mitochondrial origin.
DETD . . . agent or, if desired and possible, a therapeutically useful acid addition salt thereof or therapeutically suitable salt thereof and a **hydroximic** acid derivative of formula (I), wherein R, R.sup.1, R.sup.2, R.sup.3, A, B, X and Y are as defined above, or. . .
DETD [0043] With the compounds of formula (I), a preferable subgroup consists of **hydroximic** acid derivatives of formula (II), ##STR5##
DETD [0049] A third preferred subgroup of **hydroximic** acid derivatives of formula (I) includes cyclic compounds of formula (IV), ##STR7##
DETD [0051] A further preferred subgroup of **hydroximic** acid derivatives of formula (I) comprises compounds of formula (V), ##STR8##
DETD . . . cisplatin as cytostatic (antitumor) active agent and O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime or a therapeutically useful acid addition salt thereof as a **hydroximic** acid derivative of formula (I).
DETD [0091] The attenuating effect of **hydroximic** acid derivative of the formula I on the side effects of cytostatics was investigated by testing the **hydroximic** acid derivative compound "L". The experiments and results are being discussed below.

DETD [0115] The antitumor effect of cytostatics in combination with **hydroximic** acid derivative of the formula I was investigated by testing the **hydroximic** acid derivative compound "L". The experiments and results are being discussed below.

DETD . . . which the patient is treated with a known antitumor compound or its pharmaceutically acceptable acid addition salt supplemented by a **hydroximic** acid derivative of the formula I or a pharmaceutically acceptable acid addition salt thereof in (1-50):(1-50)% by mass.

CLM What is claimed is:

. . . active substance having antitumor effect selected from the group consisting of paclitaxel and docetaxel and an effective amount of a **hydroximic** acid derivative of the formula I ·##STR9## wherein R.sup.1 represents a hydrogen atom or a C.sub.1-5alkyl group, R.sup.2 stands for. . .

. . . pharmaceutical composition as claimed in claim 1, comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime or a physiologically acceptable acid addition salt thereof as the **hydroximic** acid derivative of the formula I.

. . . substance having antitumor effect selected from the group consisting of paclitaxel and docetaxel and an effective non-toxic amount of a **hydroximic** acid derivative of the formula I, wherein R.sup.1, R.sup.2, R.sup.3, A, X, B, R and Y are as defined in. . . addition salt thereof to the patient, wherein said tumor is sensitive to said active substance; and the administration of the **hydroximic** acid derivative or a physiologically acceptable acid addition salt thereof reduces the side effects experienced by the patient requiring treatment. . .

. . . method as claimed in claim 7, comprising administering O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a physiologically acceptable acid addition salt thereof as the **hydroximic** acid derivative of the formula I.

. . . the known active substance having antitumor activity and O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a physiologically acceptable acid addition salt thereof as the **hydroximic** acid derivative of the formula I.

. . . the known active substance having antitumor activity and O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a physiologically acceptable acid addition salt thereof as the **hydroximic** acid derivative of the formula I.

IT **51-21-8**, Fluorouracil 15663-27-1, Cisplatin
(hydroximic acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

IT **66611-37-8 66611-38-9**
(hydroximic acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

L25 ANSWER 6 OF 6 USPATFULL

AN 2002:217283 USPATFULL

TI Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an **hydroximic** acid derivative

IN Sumegi, Balazs, Pecs, HUNGARY

PA N-Gene Research Laboratories, Inc., New York, NY, United States (U.S. corporation)

PI US 6440998 B1 20020827
WO 9858676 19981230

AI US 2000-446064 20000217 (9)
WO 1998-IB961 19980622
20000217 PCT 371 date

PRAI HU 1997-1081 19970623

DT Utility

FS GRANTED

EXNAM Primary Examiner: Goldberg, Jerome D.
LREP Birch, Stewart, Kolasch & Birch, LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 751
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions having enhanced antitumor activity or reduced side effects. The compositions include both (A) a known active substance having antitumor effect or a pharmaceutically suitable salt thereof and (B) an effective amount of a **hydroximic** acid derivative of formula (I) ##STR1##

or a therapeutically useful acid addition salt thereof. Also disclosed are methods for reducing side effects in patients requiring treatment for tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an **hydroximic** acid derivative
AB . . . a known active substance having antitumor effect or a pharmaceutically suitable salt thereof and (B) an effective amount of a **hydroximic** acid derivative of formula (I) ##STR1##
SUMM **Hydroximic** acid derivatives of formula (I), ##STR2##
SUMM The U.S. Pat. No. 4,308,399 discloses compounds belonging to the scope of **hydroximic** acid derivatives of formula (I), which are useful for treatment of the diabetic angiopathy.
SUMM The EP-PS No. 417,210 describes **hydroximic** acid halides, which also fall into the scope of compounds of formula (1), possess a selective .beta.-blocking effect and are. . .
SUMM HU-PS published under No. T/66350 discloses a number of other **hydroximic** acid derivatives being within the scope of compound of formula (I). These known substances are useful in the therapy of. . .
SUMM It is known from the PCT Patent Application published under No. WO 97/13504 that **hydroximic** acid derivatives of formula (I) are useful for the prevention and treatment of disorders of mitochondrial origin.
SUMM . . . agent or, if desired and possible, a therapeutically useful acid addition salt thereof or therepautically suitable salt thereof and a **hydroximic** acid derivative of formula (I), wherein R, R.sup.1, R.sup.2, R.sup.3, A, B, X and Y are as defined above, or. . .
SUMM With the compounds of formula (I), a preferable subgroup consists of **hydroximic** acid derivatives of formula (II), ##STR5##
SUMM A third preferred subgroup of **hydroximic** acid derivatives of formula (I) includes cyclic compounds of formula (IV), ##STR7##
SUMM A further preferred subgroup of **hydroximic** acid derivatives of formula (I) comprises compounds of formula (V), ##STR8##
DETD . . . cisplatin as cytostatic (antitumor) active agent and O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime or a therapeutically useful acid addition salt thereof as a **hydroximic** acid derivative of formula (I).
DETD The attenuating effect of **hydroximic** acid derivative of the formula I on the side effects of cytostatics was investigated by testing the **hydroximic** acid derivative compound "L". The experiments and results are being discussed below.
DETD The antitumor effect of cytostatics in combination with **hydroximic** acid derivative of the formula I was investigated by testing the **hydroximic** acid derivative compound "L". The experiments and results are being discussed below.
DETD . . . which the patient is treated with a known antitumor compound or its pharmaceutically acceptable acid addition salt supplemented by a **hydroximic** acid derivative of the formula I or a pharmaceutically acceptable acid addition salt thereof in (1-50):(1-50)% by mass.
CLM What is claimed is:

. . . consisting of cisplatin and carboplatin or, optionally, a pharmaceutically suitable acid addition salt thereof and an effective amount of a **hydroximic** acid derivative of the formula I. ##STR9## wherein, R.sup.1 represents a hydrogen atom or a C.sub.1-5 alkyl group, R.sup.2 stands. . .

. . . pharmaceutical composition as claimed in claim 1, comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime or a physiologically acceptable acid addition salt thereof as the **hydroximic** acid derivative of the formula I.

. . . of cisplatin and carboplatin or, optionally, a pharmaceutically suitable acid addition salt thereof, and an effective non-toxic amount of a **hydroximic** acid derivative of formula I, wherein R.sup.1, R.sup.2, R.sup.3, A, X, B, R, and Y are as defined in claim. . . addition salt thereof to the patient, wherein said tumor is sensitive to said active substance; and the administration of the **hydroximic** acid derivative or a pharmaceutically acceptable acid addition salt thereof reduces the side effects experienced by the patient requiring treatment. . .

8. The method according to claim 7, wherein said active substance is carboplatin, and said **hydroximic** acid derivative is O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime.

9. The method according to claim 7, wherein said active substance is cisplatin and said **hydroximic** acid derivative is O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime.

. . . or a pharmaceutically suitable acid addition salt or a pharmaceutically suitable salt thereof, and an effective non-toxic amount of a **hydroximic** acid derivative of the formula I ##STR12## wherein R.sup.1, R.sup.2, R.sup.3, R, X, Y, A and B are as defined. . . from said state, wherein said tumorous state consists of tumors sensitive to said active substance having antitumor activity and said **hydroximic** acid derivative of the formula I or a pharmaceutically suitable acid addition salt thereof which reduces the side effect(s) experinced. . .

IT **51-21-8**, Fluorouracil 15663-27-1, Cisplatin
(hydroximic acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

IT **66611-37-8 66611-38-9**
(hydroximic acid deriv.-antitumor agent pharmaceutical compn. with enhanced antitumor activity and/or reduced side effects)

=>